Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506) - Wikidata - awgldk - TriplyDB

Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)

Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)

http://www.wikidata.org/entity/Q37450543

about

Adoptive T-Cell Immunotherapy Adoptive T-cell therapy for Leukemia Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens.Recruitment of Mad1 to metaphase kinetochores is sufficient to reactivate the mitotic checkpoint.The interplay between Epstein-Barr virus and the immune system: a rationale for adoptive cell therapy of EBV-related disorders Immunotherapy of human cancers using gene modified T lymphocytes.Towards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.Genetic modification of T cells Adoptive T cell therapy of cancer.Strategies to harness immunity against infectious pathogens after haploidentical stem cell transplantation Exploiting the interplay between innate and adaptive immunity to improve immunotherapeutic strategies for Epstein-Barr-virus-driven disorders Genetic modification of human T lymphocytes for the treatment of hematologic malignancies.Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation.T cells for viral infections after allogeneic hematopoietic stem cell transplant Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder.Immunotherapeutic options for Epstein-Barr virus-associated lymphoproliferative disease following transplantation.Post-transplantation lymphoproliferative disorders: diagnosis, prognosis, and current approaches to therapy.Immunotherapy against EBV-lymphoma in recipients of HSCT.Immunotherapy for EBV-associated malignancies.Ex vivo gene transfer for improved adoptive immunotherapy of cancer.Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies.T-cell therapies for Epstein-Barr virus-associated lymphomas.Genetic engineering of T cells for the immunotherapy of haematological malignancies.Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis.T-cell therapy in the treatment of post-transplant lymphoproliferative disease Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.Advances in siRNA delivery to T-cells: potential clinical applications for inflammatory disease, cancer and infection.Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation.Immunotherapy against cancer-related viruses.Current Trends and Alternative Scenarios in EBV Research.EBV-related lymphomas: new approaches to treatment.Adoptive T cell therapy for the treatment of viral infections.Generating CTLs against the subdominant EBV LMP antigens by transient expression of an A20 inhibitor with EBV LMP proteins in human DCs.Virus-Specific T Cells for the Immunocompromised Patient.Rapid salvage treatment with virus-specific T cells for therapy-resistant disease.Antithymidylate resistance enables transgene selection and cell survival for T cells in the presence of 5-fluorouracil and antifolates.Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT.Viral infection in renal transplant recipients.Probing Mitosis by Manipulating the Interactions of Mitotic Regulator Proteins Using Rapamycin-Inducible Dimerization.

P2860

Q26782845-7026D2FD-CDD0-40A1-ADCD-07AB27C70F20 Q27006934-EA0412E8-02E6-40DA-A3FA-491618B23178 Q33849560-34FB6CDD-A969-47EA-9F2D-20F618BA91F0 Q34040203-1A534553-AAB0-4ACF-9102-AEE072B323EB Q34166602-38EB31BF-671E-4F04-96D4-4B895429FA32 Q34188383-DDE4675C-D734-42B1-BB9A-D18CF6EA8A26 Q34353696-159C3EB2-9A04-4BCC-8852-6C9D2A5F2DD3 Q34644876-C39C83D0-2770-4FAB-A0B4-352191FFD0E6 Q34977470-EA9CB02F-5FCA-4EBE-AC4B-205669758AE7 Q35485612-0924A97C-932B-48EA-B796-6B7059609A5A Q35738744-D2F3E099-5A4E-4C8D-A8D2-63B99640C737 Q36366557-4C6DD16E-52F4-42E8-845B-3E45235254C6 Q36662079-B161930E-EF96-4D14-A76D-2E72CD133718 Q36956443-E09B8B65-C85F-49B6-AE9D-E6E723E36846 Q37058107-DF7C7112-3C9B-49BF-90D2-5BBA77E14FF0 Q37726624-95A97AC3-4B7D-4109-AC35-F4DAE7C2E4EC Q37793222-FBF768EE-53B3-4D4C-ACB7-840E4F86A4E4 Q37801865-2013B2E1-4177-4CD4-9F2C-F4B5C3FD883D Q37810283-E1151E2A-9680-4E39-B890-C22656D54652 Q37845178-BA31B8BB-EF9E-4234-A729-2BB20B65156F Q37854259-3DFE0952-8D75-442D-82E1-36EFEAAB4C4D Q37905034-7230DC3B-D3C4-4EFC-AA06-64F2BD70CA89 Q37948940-6AA21DBF-C425-4AAF-9495-927FB4788927 Q37965815-C4B04A79-C0C4-4227-A992-3261C0585E66 Q37968620-DB031889-48BD-46E7-BFC3-DE4FC82A2A6A Q38026758-4E862CF7-10E0-4D57-AA93-D604DB8C8B56 Q38065993-CABE0B1E-6FA1-4DCC-8CA6-D977AD0B4E9C Q38144256-6A787FA9-2AE7-4000-8DDC-C5F446A5DB08 Q38170501-03CF8EAE-6369-4E13-B692-564874DF65EE Q38778924-0DF538B7-A8AB-418F-A8A1-E5F2F6A1F5D5 Q39016336-59EEFDB9-E346-44EE-9F1D-B1ADC6C78E73 Q39441281-9923F29E-60F3-4523-B498-D81F9576B74F Q40895824-6BF1DF72-24B7-49F6-9F80-E17EDFC95E43 Q42632595-B37F15E0-AA04-4953-B230-F093D1BD7F66 Q42654381-4456534C-95DF-4F38-9ADA-E26702D986F3 Q45356159-95AE53BD-99F8-4307-8A5E-4C09804E9961 Q45878573-C53B33A5-C335-40F2-824E-2C724CAC57CE Q47603836-48D377D1-30E6-4D46-92C8-A1D8092C33B7 Q51594265-E17E9A36-C906-458A-95F5-944DE8C62DAA Q52868637-198D0FC7-63C7-4163-A319-30E2F9D6E4F8

P2860

Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)

http://www.wikidata.org/entity/Q37450543

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 16 September 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Generation of Epstein-Barr vir ...... essive drug tacrolimus (FK506)

@en

Generation of Epstein-Barr vir ...... unosuppressive drug tacrolimus

@nl

type

label

Generation of Epstein-Barr vir ...... essive drug tacrolimus (FK506)

@en

Generation of Epstein-Barr vir ...... unosuppressive drug tacrolimus

@nl

prefLabel

Generation of Epstein-Barr vir ...... essive drug tacrolimus (FK506)

@en

Generation of Epstein-Barr vir ...... unosuppressive drug tacrolimus

@nl

P1433

Q37450543-0175D022-32BA-4C74-8483-011C4B66A77F

P1476

Q37450543-2E40244F-51A7-4785-9E8E-1BB58C908F64

P2093

Q37450543-232D4661-09BF-450A-88F6-C774415AF63E

Q37450543-34048EB9-089D-4575-B30E-4247E434649D

Q37450543-7850AF87-ADC2-417F-83E9-F1A121FAB4D6

Q37450543-812B1664-6283-40D8-9AD1-F5BF7AB135D8

Q37450543-AE6EFB23-6EB3-4DAA-8B6D-621B289846AA

Q37450543-DE78298B-630D-49C2-A035-30A61C97C51A

Q37450543-F27C8BC9-6DA9-479C-BB34-C3A5EF792DD2

Q37450543-FAD555AE-32ED-461B-8537-514EFA776101

P2860

Q37450543-009C0344-8B2C-4A85-B32A-0B9EDD4F5286

Q37450543-016FD432-5AAF-4B21-A4F4-B6C046CA1386

Q37450543-04B255CE-085A-4A34-8616-FCB50C7119B4

Q37450543-1C107E0D-8A1B-4EDB-BAC5-8FCE34926CE1

Q37450543-1F3DF74D-6973-4BA0-98A5-D40755F7CB85

Q37450543-20C961F2-C042-45CC-AE2A-3C975D0B53CD

Q37450543-21662732-47D0-4092-81FD-5E7643CCECA2

Q37450543-21935167-586B-46DC-A73E-762305EF8FF2

Q37450543-23308FCB-FA0C-4514-BF61-BE71CF05BD2C

Q37450543-25A059BF-DE7A-42BA-AF6B-88F1123C6DDE

P304

Q37450543-59A8FF88-5E12-45E8-931F-0D4634E7E8D6

P31

Q37450543-56271805-BAE4-4A9A-9439-B812162BF34E

P356

Q37450543-EFAFEBB4-FBD1-4C2E-B7CF-6798E7437532

P407

Q37450543-978BEF53-4354-4C00-B314-B1C9A5B2C0F3

P433

Q37450543-4BD642DC-FC71-447B-9DEA-94012BC28F13

P478

Q37450543-5431C1B1-6E1F-41CE-B65F-EE1FBCD7CEBB

P50

Q37450543-1E0C9FE9-BD1F-4227-A52E-C40B9612193C

Q37450543-2004884E-0542-492F-A4B2-918E9FC2048D

Q37450543-809DCAA5-D64E-48B4-9C85-1709C12B8A65

P577

Q37450543-6BC7C7C5-51E3-43E1-A2B8-B2EDAD0F85E8

P5875

Q37450543-C298A823-1E54-448D-886A-53845D9DC73F

P698

Q37450543-E37D1E83-4720-47A3-B957-6E128853DC63

P921

Q37450543-4C1533B3-B332-45A7-991A-D7AFF07B39D1

Q37450543-7362B6B6-E6BD-4E4D-AA5A-26978DF7C162

Q37450543-B4231711-4F66-443D-A141-6F706481B43F

P932

Q37450543-C7A24069-58FC-4EB7-BAF1-210AD182A176

P356

BLOOD-2009-07-230482

P1433

P1476

Generation of Epstein-Barr vir ...... essive drug tacrolimus (FK506)

@en

P2093

Barbara Savoldo

http://www.w3.org/2001/XMLSchema#string

Cliona M Rooney

http://www.w3.org/2001/XMLSchema#string

Gianpietro Dotti

http://www.w3.org/2001/XMLSchema#string

Helen E Heslop

http://www.w3.org/2001/XMLSchema#string

Lan Zhang

http://www.w3.org/2001/XMLSchema#string

Leslie E Huye

http://www.w3.org/2001/XMLSchema#string

Malcolm K Brenner

http://www.w3.org/2001/XMLSchema#string

Ming Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes

Which calcineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine?

The role of adoptive immunotherapy in the prevention and treatment of lymphoproliferative disease following transplantation.

Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases.

Post-transplant lymphoproliferative disorders.

Immunodominant CD8 T cell response to Epstein-Barr virus.

Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial.

Immunotherapy for post-transplant lymphoproliferative disease.

Structures of calcineurin and its complexes with immunophilins-immunosuppressants.

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

P304

4784-4791

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2009-07-230482

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

114

http://www.w3.org/2001/XMLSchema#string

P50

Concetta Quintarelli

Biagio De Angelis

P577

2009-09-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26817031

http://www.w3.org/2001/XMLSchema#string

P698

19759356

http://www.w3.org/2001/XMLSchema#string

P921

Epstein–Barr virus

P932

2786289

http://www.w3.org/2001/XMLSchema#string